Disease · MONDO_0004790

fatty liver disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fatty liver disease. Diseases, record MONDO_0004790. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004790

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fatty liver disease; Open Targets
Open Targets ID: MONDO_0004790; Open Targets
Other names: Fatty infiltration of liver, Hepatic steatosis, Liver Steatoses, Liver steatosis, Liver, Fatty, Steatohepatitides, Steatohepatitis, Steatoses, Liver, Steatosis, Steatosis of Liver, Steatosis, Liver, Visceral Steatosis, fatty liver; Open Targets
Disease Ontology: DOID:9452; Disease Ontology
MeSH: D005234; MeSH
Highest stage of its drugs: Phase 3, for 2 of its 34 drugs, from ClinicalTrials.gov; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OBETICHOLIC ACID	CHEMBL566315	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
EXENATIDE	CHEMBL414357	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MARAVIROC	CHEMBL256907	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AMINO ACIDS	CHEMBL1201498		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CHOLIC ACID	CHEMBL205596	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EPLERENONE	CHEMBL1095097	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GLP1R	Glucagon-like peptide 1 receptor	3	Glucagon-like peptide 1 receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2740	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	2	Peroxisome proliferator-activated receptor gamma agonist	Phase 2	https://conductscience.org/library/genes/5468	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	2	Sodium/glucose cotransporter 2 inhibitor	Early phase 1	https://conductscience.org/library/genes/6524	Drugs and targets
THRB	Thyroid hormone receptor	2	Thyroid hormone receptor agonist; Thyroid hormone receptor beta-1 agonist	Phase 2	https://conductscience.org/library/genes/7068	Drugs and targets
ADRB3	Beta-3 adrenergic receptor	1	Beta-3 adrenergic receptor agonist	Phase 1	https://conductscience.org/library/genes/155	Drugs and targets
APOC3	Apolipoprotein C-III mRNA 3'UTR	1	Apolipoprotein C-III mRNA 3'UTR antisense inhibitor	Phase 2	https://conductscience.org/library/genes/345	Drugs and targets
CCR5	C-C chemokine receptor type 5	1	C-C chemokine receptor type 5 antagonist	Phase 2/3	https://conductscience.org/library/genes/1234	Drugs and targets
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/56901	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00001723	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases	Phase 2	200	2012-12-18	Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome	ORLISTAT	Its record names the disease	ClinicalTrials.gov
NCT00441272	Pioglitazone to Treat Fatty Liver in People With HIV Infection	Phase 2	100	2010-02-19	HIV Infections, Hepatic Steatosis, Insulin Resistance	PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT02157974	Liver and Fat Regulation in Overweight Adolescent Girls	Phase 2/3	92	2024-06-04	Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity	EXENATIDE	Its record names the disease	ClinicalTrials.gov
NCT03919929	Treating PCOS With Semaglutide vs Active Lifestyle Intervention	Phase 2/3	60	2025-11-25	PCOS, Adolescent Obesity, NAFLD	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT04216589	Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)	Phase 2	51	2024-05-17	HIV Infections, Non-Alcoholic Fatty Liver Disease	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT01431521	Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)	Phase 1	31	2016-03-25	Non-alcoholic Fatty Liver Disease	PIOGLITAZONE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01284634	Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease	Phase 2	25	2014-01-20	Fatty Liver	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT00457639	Cholic Acid for Hepatic Steatosis in Lipodystrophy	Phase 2	18	2019-01-15	Hepatic Steatosis	CHOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00799578	A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)	Phase 1/2	13	2014-01-31	Fatty Liver	CYSTEAMINE	Its record names the disease	ClinicalTrials.gov
NCT02430077	Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients	Phase 2	10	2023-12-13	Familial Partial Lipodystrophy	OBETICHOLIC ACID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Orlistat vs Placebo: serious adverse events	0 of 100	2 of 100	200	NCT00001723	Trial comparisons
Diet Intervention vs GLP-1 Intervention: deaths from any cause	0 of 17	0 of 38	55	NCT03919929	Trial comparisons
Diet Intervention vs GLP-1 Intervention: serious adverse events	0 of 17	0 of 38	55	NCT03919929	Trial comparisons
Cholic Acid vs Placebo: deaths from any cause	0 of 14	0 of 15	29	NCT00457639	Trial comparisons
Cholic Acid vs Placebo: serious adverse events	0 of 14	0 of 15	29	NCT00457639	Trial comparisons
Active Capsule of Obeticholic Acid vs Placebo for Obeticholic Acid: deaths from any cause	0 of 10	0 of 10	20	NCT02430077	Trial comparisons
Active Capsule of Obeticholic Acid vs Placebo for Obeticholic Acid: serious adverse events	0 of 10	0 of 10	20	NCT02430077	Trial comparisons
ISIS 304801 vs Placebo: deaths from any cause	0 of 2	0 of 3	5	NCT02639286	Trial comparisons
ISIS 304801 vs Placebo: serious adverse events	1 of 2	0 of 3	5	NCT02639286	Trial comparisons

Papers from its trials27

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29509992	RESULT	1	PubMed
26555703	RESULT	1	PubMed
23906374	RESULT	1	PubMed
23447519	RESULT	1	PubMed
23398530	RESULT	1	PubMed
22431131	RESULT	1	PubMed
21094444	RESULT	1	PubMed
15112907	RESULT	1	PubMed
12126214	RESULT	1	PubMed
12105286	RESULT	1	PubMed

1 to 10 of 27

See all 27 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004790

GET https://conductscience.org/api/diseases/v1/MONDO_0004790/drugs?page=2

API reference For AI assistants